micafungin ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antifungal antibiotics 1798 235114-32-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • mycamine
  • micafungin
  • micafungin sodium
  • FK-463
  • FK463
A cyclic lipo-hexapeptide echinocandin antifungal agent that is used for the treatment and prevention of CANDIDIASIS.
  • Molecular weight: 1270.28
  • Formula: C56H71N9O23S
  • CLOGP: -1.99
  • LIPINSKI: 3
  • HAC: 32
  • HDO: 16
  • TPSA: 510.14
  • ALOGS: -3.77
  • ROTB: 18

Drug dosage:

DoseUnitRoute
0.10 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 1 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 6.30 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 0.21 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.17 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.00 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 16 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
March 16, 2005 FDA FUJISAWA HLTHCARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 245.06 26.49 155 6710 105390 56179812
Pre-engraftment immune reaction 171.39 26.49 29 6836 209 56284993
Human herpesvirus 6 infection 162.37 26.49 42 6823 2640 56282562
Encephalitis viral 146.16 26.49 35 6830 1600 56283602
Multiple organ dysfunction syndrome 115.95 26.49 75 6790 52695 56232507
Cytomegalovirus test positive 104.40 26.49 30 6835 2796 56282406
Aplastic anaemia 101.76 26.49 39 6826 8889 56276313
Acute graft versus host disease 96.96 26.49 31 6834 4144 56281058
Mucormycosis 96.04 26.49 28 6837 2746 56282456
Aspergillus infection 93.72 26.49 35 6830 7430 56277772
Sepsis 92.66 26.49 99 6766 139741 56145461
Bronchopulmonary aspergillosis 90.26 26.49 35 6830 8229 56276973
Bacterial sepsis 83.63 26.49 27 6838 3722 56281480
Acute graft versus host disease in skin 83.60 26.49 26 6839 3176 56282026
Pneumonia fungal 80.41 26.49 28 6837 4865 56280337
Hepatic function abnormal 73.12 26.49 48 6817 34510 56250692
Septic shock 70.95 26.49 59 6806 60776 56224426
Systemic candida 68.23 26.49 22 6843 3019 56282183
Cytomegalovirus viraemia 67.91 26.49 25 6840 5095 56280107
Thrombotic microangiopathy 65.86 26.49 29 6836 9382 56275820
Cytomegalovirus infection 64.63 26.49 36 6829 19260 56265942
Engraft failure 61.22 26.49 13 6852 342 56284860
Gastrointestinal fungal infection 58.91 26.49 12 6853 256 56284946
Pyrexia 58.03 26.49 145 6720 418628 55866574
Pathogen resistance 57.07 26.49 23 6842 5977 56279225
Meningoencephalitis herpetic 55.85 26.49 15 6850 1089 56284113
Liver abscess 54.21 26.49 18 6847 2708 56282494
Candida infection 52.70 26.49 35 6830 25632 56259570
Respiratory failure 52.06 26.49 61 6804 95001 56190201
Off label use 51.11 26.49 166 6699 556014 55729188
Graft versus host disease 51.04 26.49 22 6843 6759 56278443
Sinus polyp 50.63 26.49 11 6854 323 56284879
Systemic mycosis 50.52 26.49 14 6851 1143 56284059
Enterococcal sepsis 48.59 26.49 14 6851 1316 56283886
Weissella infection 47.47 26.49 7 6858 17 56285185
Product use in unapproved indication 47.16 26.49 71 6794 140751 56144451
Haemophagocytic lymphohistiocytosis 46.76 26.49 23 6842 9549 56275653
Fatigue 43.63 26.49 21 6844 788531 55496671
Aspartate aminotransferase increased 43.55 26.49 52 6813 82550 56202652
Enterobacter infection 42.61 26.49 14 6851 2038 56283164
Fungaemia 42.13 26.49 14 6851 2110 56283092
Platelet count decreased 41.98 26.49 58 6807 106325 56178877
Hypoalbuminaemia 41.68 26.49 22 6843 10577 56274625
Arthralgia 41.47 26.49 6 6859 501663 55783539
Plasma cell leukaemia 41.21 26.49 12 6853 1171 56284031
Geotrichum infection 41.05 26.49 10 6855 491 56284711
Disseminated intravascular coagulation 40.66 26.49 26 6839 17859 56267343
Fungal infection 40.53 26.49 33 6832 32960 56252242
Nasal abscess 40.41 26.49 8 6857 147 56285055
Biloma 40.28 26.49 7 6858 60 56285142
Acute myeloid leukaemia recurrent 38.18 26.49 12 6853 1516 56283686
Encephalitis fungal 37.85 26.49 6 6859 27 56285175
Chronic graft versus host disease 36.29 26.49 14 6851 3242 56281960
Epstein-Barr virus associated lymphoproliferative disorder 36.23 26.49 12 6853 1791 56283411
Pain 36.12 26.49 18 6847 663166 55622036
Mucosal erosion 35.71 26.49 11 6854 1300 56283902
Cytokine release syndrome 35.62 26.49 20 6845 10855 56274347
Alanine aminotransferase increased 35.35 26.49 50 6815 93612 56191590
Encephalitis Japanese B 35.24 26.49 6 6859 45 56285157
Enterococcal infection 34.31 26.49 17 6848 7167 56278035
Neutropenia 32.19 26.49 64 6801 158103 56127099
Renal impairment 31.81 26.49 44 6821 80669 56204533
Acute respiratory distress syndrome 31.38 26.49 24 6841 21902 56263300
Pleural effusion 31.32 26.49 45 6820 85435 56199767
Trichosporon infection 30.01 26.49 7 6858 285 56284917
Acute lymphocytic leukaemia recurrent 29.66 26.49 11 6854 2286 56282916
Cryptosporidiosis infection 29.30 26.49 7 6858 316 56284886
Acute graft versus host disease in intestine 28.92 26.49 10 6855 1700 56283502
Aspergillus test positive 28.83 26.49 7 6858 339 56284863
Varicella zoster virus infection 28.40 26.49 11 6854 2573 56282629
Fungal sepsis 28.29 26.49 9 6856 1182 56284020
Pneumonia 28.23 26.49 111 6754 406987 55878215
Oral fungal infection 28.17 26.49 11 6854 2629 56282573
Drug ineffective for unapproved indication 28.03 26.49 24 6841 25669 56259533
Fall 27.88 26.49 5 6860 357505 55927697
Mixed liver injury 27.09 26.49 12 6853 3932 56281270
Malaise 26.90 26.49 6 6859 367854 55917348
Liver disorder 26.84 26.49 30 6835 44340 56240862
Rash morbilliform 26.79 26.49 11 6854 2996 56282206

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 202.04 20.14 232 11049 121617 31564446
Aplastic anaemia 192.10 20.14 84 11197 9119 31676944
Acute graft versus host disease in skin 151.45 20.14 59 11222 4773 31681290
Multiple organ dysfunction syndrome 142.70 20.14 147 11134 68056 31618007
Aspergillus infection 141.47 20.14 73 11208 11455 31674608
Bronchopulmonary aspergillosis 140.94 20.14 77 11204 13557 31672506
Candida infection 103.05 20.14 67 11214 16191 31669872
Disseminated intravascular coagulation 97.91 20.14 71 11210 20466 31665597
Herpes simplex oesophagitis 93.46 20.14 20 11261 174 31685889
Cytomegalovirus viraemia 92.45 20.14 46 11235 6679 31679384
Graft versus host disease 89 20.14 52 11229 10395 31675668
Acute graft versus host disease in intestine 86.84 20.14 33 11248 2493 31683570
Acute graft versus host disease 84.32 20.14 42 11239 6111 31679952
Mucormycosis 79.24 20.14 39 11242 5531 31680532
Fungaemia 78.04 20.14 30 11251 2339 31683724
Trichosporon infection 76.94 20.14 22 11259 675 31685388
Fungal infection 68.64 20.14 50 11231 14501 31671562
Cystitis haemorrhagic 66.32 20.14 34 11247 5255 31680808
Venoocclusive liver disease 63.41 20.14 37 11244 7375 31678688
Fusarium infection 63.30 20.14 21 11260 1065 31684998
Cytomegalovirus test positive 62.74 20.14 29 11252 3576 31682487
Product use in unapproved indication 62.47 20.14 120 11161 99051 31587012
Respiratory failure 61.76 20.14 121 11160 101328 31584735
Pyrexia 61.07 20.14 241 11040 303599 31382464
Acute graft versus host disease in liver 54.25 20.14 20 11261 1388 31684675
Sepsis 53.47 20.14 146 11135 151783 31534280
Pre-engraftment immune reaction 52.22 20.14 11 11270 88 31685975
Fatigue 51.09 20.14 28 11253 335178 31350885
Acute myeloid leukaemia recurrent 51.07 20.14 21 11260 1953 31684110
Septic shock 49.13 20.14 86 11195 66072 31619991
Cytomegalovirus infection 47.52 20.14 51 11230 24656 31661407
Systemic candida 47.38 20.14 23 11258 3163 31682900
Cytokine release syndrome 46.25 20.14 42 11239 16600 31669463
Glomerulosclerosis 46.11 20.14 15 11266 715 31685348
Human herpesvirus 6 infection 44.53 20.14 19 11262 1938 31684125
Mucosal inflammation 44.52 20.14 58 11223 34369 31651694
Dizziness 43.47 20.14 9 11272 199138 31486925
Enterococcal infection 43.45 20.14 31 11250 8700 31677363
Chronic graft versus host disease 43.14 20.14 24 11257 4368 31681695
Staphylococcal sepsis 42.18 20.14 31 11250 9106 31676957
Botulism 41.14 20.14 10 11271 160 31685903
Hepatic function abnormal 40.69 20.14 61 11220 41161 31644902
Off label use 39.51 20.14 234 11047 347040 31339023
Encephalitis viral 39.31 20.14 15 11266 1145 31684918
Candida sepsis 38.95 20.14 15 11266 1174 31684889
Pneumonia fungal 37.45 20.14 25 11256 6304 31679759
Drug ineffective 36.65 20.14 253 11028 395320 31290743
Systemic mycosis 35.98 20.14 15 11266 1444 31684619
Haemophagocytic lymphohistiocytosis 35.48 20.14 31 11250 11647 31674416
Thymus hypoplasia 34.63 20.14 9 11272 191 31685872
Lymphoid tissue hypoplasia 34.63 20.14 9 11272 191 31685872
Disseminated aspergillosis 34 20.14 11 11270 515 31685548
Fall 33.86 20.14 12 11269 186077 31499986
Sinusitis fungal 33.30 20.14 11 11270 550 31685513
Cerebral aspergillosis 33.23 20.14 14 11267 1384 31684679
Cholestatic liver injury 31.77 20.14 15 11266 1939 31684124
Bacteraemia 31.47 20.14 35 11246 17599 31668464
Graft versus host disease in gastrointestinal tract 31.43 20.14 18 11263 3461 31682602
Kidney fibrosis 30.68 20.14 15 11266 2095 31683968
Disseminated cryptococcosis 30.27 20.14 13 11268 1347 31684716
Geotrichum infection 30.24 20.14 10 11271 502 31685561
Tumour lysis syndrome 30.00 20.14 32 11249 15353 31670710
Cystitis viral 29.94 20.14 10 11271 518 31685545
Necrotising oesophagitis 29.94 20.14 10 11271 518 31685545
Myocardial infarction 29.64 20.14 3 11278 113451 31572612
Drug resistance 29.51 20.14 39 11242 23414 31662649
Immunosuppressant drug level increased 29.18 20.14 20 11261 5265 31680798
Mucosal disorder 28.77 20.14 13 11268 1521 31684542
Graft versus host disease in skin 28.26 20.14 17 11264 3580 31682483
Idiopathic pneumonia syndrome 28.21 20.14 8 11273 238 31685825
Rhinocerebral mucormycosis 28.03 20.14 9 11272 411 31685652
Delayed graft function 27.44 20.14 14 11267 2141 31683922
Engraft failure 27.40 20.14 9 11272 442 31685621
Platelet count decreased 27.40 20.14 94 11187 110341 31575722
Pseudomembranous colitis 27.21 20.14 15 11266 2680 31683383
Renal failure 27.21 20.14 101 11180 123229 31562834
Product dose omission issue 27.05 20.14 3 11278 105583 31580480
Vascular device infection 26.91 20.14 16 11265 3299 31682764
Klebsiella infection 26.33 20.14 22 11259 7781 31678282
Enterococcal sepsis 25.64 20.14 12 11269 1521 31684542
Reactive gastropathy 25.37 20.14 7 11274 188 31685875
Pseudomonal sepsis 24.84 20.14 15 11266 3181 31682882
Functional gastrointestinal disorder 24.61 20.14 13 11268 2135 31683928
Device related sepsis 24.26 20.14 14 11267 2730 31683333
Ophthalmic vein thrombosis 23.52 20.14 5 11276 42 31686021
Thrombotic microangiopathy 22.89 20.14 22 11259 9329 31676734
Somnolence 22.72 20.14 4 11277 99441 31586622
Liver disorder 22.52 20.14 39 11242 29668 31656395
Infection 22.32 20.14 72 11209 81859 31604204
Bacterial toxaemia 22.27 20.14 6 11275 147 31685916
Depression 22.23 20.14 3 11278 90812 31595251
Antithrombin III decreased 21.99 20.14 7 11274 311 31685752
Haemorrhagic necrotic pancreatitis 21.44 20.14 6 11275 170 31685893
Alternaria infection 21.41 20.14 7 11274 339 31685724
Cerebral ventricle collapse 21.33 20.14 5 11276 68 31685995
Engraftment syndrome 21.26 20.14 9 11272 900 31685163
Arthralgia 21.09 20.14 14 11267 151410 31534653
Weight decreased 20.69 20.14 16 11265 159936 31526127
Blood beta-D-glucan increased 20.36 20.14 7 11274 396 31685667
Neurological symptom 20.31 20.14 14 11267 3717 31682346
Pain in extremity 20.26 20.14 8 11273 116195 31569868
Blood bilirubin increased 20.23 20.14 41 11240 35095 31650968
Blast cell count increased 20.20 20.14 9 11272 1018 31685045
Adenoviral haemorrhagic cystitis 20.18 20.14 7 11274 407 31685656

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 397.37 21.56 354 16679 203964 70707447
Aplastic anaemia 292.13 21.56 120 16913 16596 70894815
Aspergillus infection 228.94 21.56 103 16930 17765 70893646
Multiple organ dysfunction syndrome 222.34 21.56 194 16839 108321 70803090
Pre-engraftment immune reaction 207.78 21.56 40 16993 301 70911110
Bronchopulmonary aspergillosis 201.03 21.56 99 16934 20903 70890508
Human herpesvirus 6 infection 177.67 21.56 60 16973 4799 70906612
Mucormycosis 176.46 21.56 68 16965 7946 70903465
Encephalitis viral 168.51 21.56 49 16984 2393 70909018
Cytomegalovirus viraemia 154.90 21.56 69 16964 11616 70899795
Acute graft versus host disease 148.05 21.56 63 16970 9499 70901912
Candida infection 142.88 21.56 94 16939 34379 70877032
Acute graft versus host disease in skin 130.66 21.56 53 16980 7084 70904327
Sepsis 130.06 21.56 220 16813 244325 70667086
Product use in unapproved indication 121.52 21.56 195 16838 207283 70704128
Disseminated intravascular coagulation 121.04 21.56 84 16949 33514 70877897
Fungaemia 113.10 21.56 41 16992 4041 70907370
Trichosporon infection 111.43 21.56 29 17004 932 70910479
Cytomegalovirus infection 108.37 21.56 84 16949 39674 70871737
Fungal infection 108.36 21.56 82 16951 37385 70874026
Systemic candida 104.98 21.56 43 16990 5891 70905520
Graft versus host disease 104.01 21.56 57 16976 14966 70896445
Pyrexia 100.95 21.56 347 16686 606605 70304806
Respiratory failure 97.93 21.56 158 16875 168577 70742834
Hepatic function abnormal 97.76 21.56 100 16933 67896 70843515
Septic shock 95.54 21.56 126 16907 112132 70799279
Pneumonia fungal 95.45 21.56 47 16986 9906 70901505
Cytomegalovirus test positive 90.96 21.56 38 16995 5470 70905941
Herpes simplex oesophagitis 88.81 21.56 20 17013 343 70911068
Acute graft versus host disease in intestine 86.21 21.56 33 17000 3783 70907628
Fatigue 84.05 21.56 47 16986 824272 70087139
Enterococcal infection 78.61 21.56 47 16986 14535 70896876
Cytokine release syndrome 74.47 21.56 57 16976 26410 70885001
Systemic mycosis 72.37 21.56 26 17007 2496 70908915
Venoocclusive liver disease 69.76 21.56 39 16994 10639 70900772
Platelet count decreased 69.00 21.56 140 16893 178082 70733329
Geotrichum infection 68.40 21.56 20 17013 995 70910416
Acute myeloid leukaemia recurrent 67.52 21.56 26 17007 3028 70908383
Arthralgia 67.03 21.56 19 17014 503371 70408040
Haemophagocytic lymphohistiocytosis 65.89 21.56 47 16986 19565 70891846
Disseminated aspergillosis 63.37 21.56 18 17015 807 70910604
Pathogen resistance 61.88 21.56 39 16994 13240 70898171
Mucosal inflammation 58.99 21.56 77 16956 67773 70843638
Fall 58.67 21.56 17 17016 444079 70467332
Off label use 58.41 21.56 340 16693 742720 70168691
Pain 58.23 21.56 40 16993 628776 70282635
Fusarium infection 57.89 21.56 20 17013 1712 70909699
Drug ineffective 57.88 21.56 404 16629 939348 69972063
Meningoencephalitis herpetic 56.71 21.56 20 17013 1819 70909592
Bacterial sepsis 55.66 21.56 30 17003 7617 70903794
Dizziness 55.65 21.56 21 17012 464120 70447291
Lymphoid tissue hypoplasia 54.93 21.56 15 17018 581 70910830
Drug resistance 54.56 21.56 56 16977 38134 70873277
Thymus hypoplasia 53.90 21.56 15 17018 624 70910787
Enterococcal sepsis 53.80 21.56 21 17012 2536 70908875
Acute graft versus host disease in liver 53.41 21.56 19 17014 1773 70909638
Cystitis haemorrhagic 52.39 21.56 30 17003 8563 70902848
Candida sepsis 51.89 21.56 20 17013 2335 70909076
Chronic graft versus host disease 50.51 21.56 27 17006 6743 70904668
Headache 49.74 21.56 40 16993 580365 70331046
Disseminated cryptococcosis 49.69 21.56 18 17015 1769 70909642
Tumour lysis syndrome 49.39 21.56 41 16992 21319 70890092
Bacteraemia 49.33 21.56 47 16986 29262 70882149
Hypoalbuminaemia 49.06 21.56 39 16994 19083 70892328
Pneumonia 48.84 21.56 276 16757 595956 70315455
Engraft failure 48.82 21.56 14 17019 650 70910761
Aspartate aminotransferase increased 48.22 21.56 99 16934 126879 70784532
Blood bilirubin increased 47.49 21.56 65 16968 59836 70851575
Thrombotic microangiopathy 47.07 21.56 37 16996 17811 70893600
Gastrointestinal fungal infection 46.40 21.56 12 17021 376 70911035
Cerebral aspergillosis 46.27 21.56 17 17016 1739 70909672
Staphylococcal sepsis 44.69 21.56 32 17001 13395 70898016
Liver abscess 43.67 21.56 23 17010 5576 70905835
Malaise 43.52 21.56 25 17008 432907 70478504
Renal failure 43.18 21.56 121 16912 188949 70722462
Weissella infection 42.72 21.56 7 17026 17 70911394
Acute respiratory distress syndrome 42.53 21.56 51 16982 41203 70870208
Alanine aminotransferase increased 42.51 21.56 103 16930 147377 70764034
Nasopharyngitis 41.80 21.56 3 17030 222203 70689208
Pseudomonal sepsis 41.08 21.56 22 17011 5515 70905896
Cholestatic liver injury 40.91 21.56 20 17013 4148 70907263
Product dose omission issue 40.72 21.56 3 17030 217465 70693946
Renal impairment 39.86 21.56 99 16934 143838 70767573
Peripheral swelling 39.74 21.56 5 17028 236558 70674853
Glomerulosclerosis 39.43 21.56 13 17020 964 70910447
Sinus polyp 39.40 21.56 11 17022 463 70910948
Pain in extremity 39.03 21.56 15 17018 328067 70583344
Pleural effusion 38.51 21.56 93 16940 132771 70778640
White blood cell count decreased 37.97 21.56 108 16925 170033 70741378
Botulism 37.14 21.56 10 17023 367 70911044
Mucosal disorder 36.43 21.56 17 17016 3181 70908230
Alopecia 36.43 21.56 3 17030 198487 70712924
Neutrophil count decreased 36.36 21.56 69 16964 83487 70827924
Bacterial infection 36.31 21.56 38 16995 26454 70884957
Engraftment syndrome 36.15 21.56 13 17020 1251 70910160
Delayed graft function 35.86 21.56 17 17016 3296 70908115
Cystitis viral 35.48 21.56 11 17022 669 70910742
Blast cell count increased 35.44 21.56 13 17020 1324 70910087
Drug intolerance 35.06 21.56 6 17027 225681 70685730
Acute lymphocytic leukaemia recurrent 35.02 21.56 19 17014 4885 70906526
Asthenia 35.02 21.56 35 16998 457631 70453780
Necrotising oesophagitis 34.96 21.56 11 17022 702 70910709
Nasal abscess 34.85 21.56 8 17025 150 70911261
Immunosuppressant drug level increased 33.81 21.56 22 17011 7885 70903526
Mixed liver injury 33.31 21.56 20 17013 6229 70905182
Idiopathic pneumonia syndrome 33.14 21.56 10 17023 555 70910856
Acute myeloid leukaemia 33.12 21.56 39 16994 30901 70880510
Weight increased 32.47 21.56 9 17024 242322 70669089
Dyspnoea 31.85 21.56 88 16945 769972 70141439
Graft versus host disease in gastrointestinal tract 31.62 21.56 19 17014 5925 70905486
Pulmonary mucormycosis 31.54 21.56 11 17022 968 70910443
Vascular device infection 31.08 21.56 21 17012 8009 70903402
Neutropenia 30.94 21.56 133 16900 257023 70654388
Staphylococcal infection 30.90 21.56 50 16983 53354 70858057
Cytomegalovirus enterocolitis 30.57 21.56 12 17021 1471 70909940
Rhinocerebral mucormycosis 30.27 21.56 10 17023 746 70910665
Klebsiella infection 30.10 21.56 26 17007 14266 70897145
Graft versus host disease in skin 29.96 21.56 18 17015 5612 70905799
Enterobacter infection 29.75 21.56 16 17017 4044 70907367
Lymphocyte count decreased 29.72 21.56 44 16989 43495 70867916
Biloma 29.61 21.56 7 17026 150 70911261
Graft versus host disease in liver 29.56 21.56 12 17021 1606 70909805
Depression 29.38 21.56 6 17027 198968 70712443
Adenovirus infection 29.32 21.56 20 17013 7748 70903663
Pruritus 29.31 21.56 24 17009 345536 70565875
Encephalitis Japanese B 28.95 21.56 6 17027 68 70911343
Device related infection 28.69 21.56 37 16996 32148 70879263
Oesophagitis 28.41 21.56 31 17002 22621 70888790
Nephropathy toxic 27.99 21.56 28 17005 18486 70892925
Rash morbilliform 27.89 21.56 17 17016 5438 70905973
Plasma cell leukaemia 27.87 21.56 12 17021 1859 70909552
Epstein-Barr virus infection 27.77 21.56 24 17009 13174 70898237
Staphylococcal bacteraemia 27.14 21.56 22 17011 11060 70900351
Mucosal erosion 26.60 21.56 12 17021 2077 70909334
Drug hypersensitivity 26.56 21.56 15 17018 262444 70648967
Hypersensitivity 26.50 21.56 11 17022 229801 70681610
Pseudomembranous colitis 26.32 21.56 16 17017 5095 70906316
Neutropenic colitis 26.31 21.56 16 17017 5098 70906313
Toxicity to various agents 26.17 21.56 32 17001 382140 70529271
Chest pain 25.95 21.56 14 17019 251246 70660165
Cytopenia 25.82 21.56 26 17007 17297 70894114
Blood pressure increased 25.25 21.56 7 17026 188510 70722901
Blood urea increased 25.23 21.56 42 16991 45867 70865544
Drug-induced liver injury 25.23 21.56 47 16986 56066 70855345
Abdominal discomfort 25.20 21.56 10 17023 214648 70696763
Gait disturbance 24.55 21.56 7 17026 185099 70726312
Liver disorder 24.53 21.56 49 16984 61519 70849892
Bacterial toxaemia 24.23 21.56 6 17027 157 70911254
Kidney fibrosis 24.17 21.56 13 17020 3287 70908124
Clostridium difficile colitis 23.79 21.56 32 17001 28964 70882447
Drug ineffective for unapproved indication 23.55 21.56 37 16996 38501 70872910
Sinusitis fungal 23.49 21.56 11 17022 2074 70909337
Hypokalaemia 23.38 21.56 77 16956 131111 70780300
Leukaemia recurrent 23.36 21.56 12 17021 2763 70908648
Platelet transfusion 23.33 21.56 11 17022 2107 70909304
Candida test positive 23.20 21.56 9 17024 1069 70910342
Pulmonary haemorrhage 23.14 21.56 22 17011 13651 70897760
Brain abscess 22.76 21.56 14 17019 4552 70906859
Aspergillus test positive 22.70 21.56 8 17025 726 70910685
Device related sepsis 22.22 21.56 15 17018 5713 70905698
Gamma-glutamyltransferase increased 22.22 21.56 42 16991 50643 70860768
Reactive gastropathy 21.98 21.56 7 17026 465 70910946
Oral disorder 21.93 21.56 18 17015 9211 70902200
Blood lactate dehydrogenase increased 21.85 21.56 34 16999 35093 70876318
Myocardial infarction 21.84 21.56 7 17026 171638 70739773
Hyperbilirubinaemia 21.79 21.56 27 17006 22541 70888870
Viral haemorrhagic cystitis 21.69 21.56 10 17023 1821 70909590
Oral fungal infection 21.66 21.56 12 17021 3214 70908197

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J02AX05 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOTICS FOR SYSTEMIC USE
ANTIMYCOTICS FOR SYSTEMIC USE
Other antimycotics for systemic use
FDA CS M0519359 Lipopeptides
FDA EPC N0000175507 Echinocandin Antifungal
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000935 Antifungal Agents
CHEBI has role CHEBI:35441 antiinfective agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Candidiasis of the esophagus indication 20639004 DOID:13146
Disseminated candidiasis indication 70572005
Candidal septicemia indication 187022007
Candidemia indication 432261003
Prevention of Disseminated Candidiasis indication
Candida Peritonitis indication
Oropharyngeal Candidiasis off-label use
Intravascular hemolysis contraindication 15601008
Kidney disease contraindication 90708001 DOID:557
Liver function tests abnormal contraindication 166603001




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.09 acidic
pKa2 10.7 acidic
pKa3 12.91 acidic
pKa4 13.44 acidic
pKa5 13.52 acidic
pKa6 13.9 acidic
pKa7 13.91 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 100MG BASE/VIAL MYCAMINE ASTELLAS N021506 June 27, 2006 RX INJECTABLE INTRAVENOUS Dec. 20, 2022 TREATMENT OF CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABSCESSES WITHOUT MENINGOENCEPHALITIS AND/OR OCULAR DISSEMINATION IN PEDIATRIC PATIENTS YOUNGER THAN 4 MONTHS OF AGE
EQ 50MG BASE/VIAL MYCAMINE ASTELLAS N021506 March 16, 2005 RX INJECTABLE INTRAVENOUS Dec. 20, 2022 TREATMENT OF CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABSCESSES WITHOUT MENINGOENCEPHALITIS AND/OR OCULAR DISSEMINATION IN PEDIATRIC PATIENTS YOUNGER THAN 4 MONTHS OF AGE
EQ 100MG BASE/VIAL MYCAMINE ASTELLAS N021506 June 27, 2006 RX INJECTABLE INTRAVENOUS June 20, 2023 PEDIATRIC EXCLUSIVITY
EQ 50MG BASE/VIAL MYCAMINE ASTELLAS N021506 March 16, 2005 RX INJECTABLE INTRAVENOUS June 20, 2023 PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Beta-1,3-glucan synthase catalytic subunit 1 Enzyme INHIBITOR CHEMBL CHEMBL
Beta-1,3-glucan synthase Unclassified WOMBAT-PK

External reference:

IDSource
D02465 KEGG_DRUG
208538-73-2 SECONDARY_CAS_RN
4024920 VANDF
4024948 VANDF
C1120386 UMLSCUI
CHEBI:600520 CHEBI
CHEMBL1237070 ChEMBL_ID
CHEMBL457547 ChEMBL_ID
D000077551 MESH_DESCRIPTOR_UI
DB01141 DRUGBANK_ID
8069 INN_ID
R10H71BSWG UNII
477468 PUBCHEM_CID
325887 RXNORM
19567 MMSL
334346 MMSL
66902 MMSL
d05487 MMSL
010714 NDDF
010715 NDDF
416127003 SNOMEDCT_US
416233001 SNOMEDCT_US
426226002 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Micafungin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9361 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 10 mg INTRAVENOUS ANDA 27 sections
Micafungin HUMAN PRESCRIPTION DRUG LABEL 1 0143-9362 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS ANDA 27 sections
Mycamine HUMAN PRESCRIPTION DRUG LABEL 1 0469-3211 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS NDA 27 sections
Mycamine HUMAN PRESCRIPTION DRUG LABEL 1 0469-3211 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS NDA 27 sections
Mycamine HUMAN PRESCRIPTION DRUG LABEL 1 0469-3211 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS NDA 27 sections
Mycamine HUMAN PRESCRIPTION DRUG LABEL 1 0469-3211 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS NDA 27 sections
Mycamine HUMAN PRESCRIPTION DRUG LABEL 1 0469-3211 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS NDA 27 sections
Mycamine HUMAN PRESCRIPTION DRUG LABEL 1 0469-3250 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 10 mg INTRAVENOUS NDA 27 sections
Mycamine HUMAN PRESCRIPTION DRUG LABEL 1 0469-3250 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 10 mg INTRAVENOUS NDA 27 sections
Mycamine HUMAN PRESCRIPTION DRUG LABEL 1 0469-3250 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 10 mg INTRAVENOUS NDA 27 sections
Mycamine HUMAN PRESCRIPTION DRUG LABEL 1 0469-3250 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 10 mg INTRAVENOUS NDA 27 sections
Micafungin HUMAN PRESCRIPTION DRUG LABEL 1 25021-190 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS ANDA 29 sections
Micafungin HUMAN PRESCRIPTION DRUG LABEL 1 25021-190 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS ANDA 29 sections
Micafungin HUMAN PRESCRIPTION DRUG LABEL 1 25021-191 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 mg INTRAVENOUS ANDA 29 sections
Micafungin HUMAN PRESCRIPTION DRUG LABEL 1 25021-191 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 mg INTRAVENOUS ANDA 29 sections
Micafungin HUMAN PRESCRIPTION DRUG LABEL 1 42023-229 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 10 mg INTRAVENOUS NDA 26 sections
Micafungin HUMAN PRESCRIPTION DRUG LABEL 1 42023-230 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS NDA 26 sections
Micafungin HUMAN PRESCRIPTION DRUG LABEL 1 60505-6119 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 10 mg INTRAVENOUS ANDA 27 sections
Micafungin HUMAN PRESCRIPTION DRUG LABEL 1 60505-6120 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS ANDA 27 sections
Micafungin HUMAN PRESCRIPTION DRUG LABEL 1 63323-728 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS ANDA 30 sections
Micafungin HUMAN PRESCRIPTION DRUG LABEL 1 63323-728 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS ANDA 30 sections
Micafungin HUMAN PRESCRIPTION DRUG LABEL 1 63323-729 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 mg INTRAVENOUS ANDA 30 sections
Micafungin HUMAN PRESCRIPTION DRUG LABEL 1 63323-729 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 mg INTRAVENOUS ANDA 30 sections
Micafungin HUMAN PRESCRIPTION DRUG LABEL 1 63323-729 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 mg INTRAVENOUS ANDA 30 sections
Micafungin HUMAN PRESCRIPTION DRUG LABEL 1 70594-036 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 10 mg INTRAVENOUS ANDA 34 sections
Micafungin HUMAN PRESCRIPTION DRUG LABEL 1 70594-037 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 20 mg INTRAVENOUS ANDA 34 sections
Micafungin HUMAN PRESCRIPTION DRUG LABEL 1 71288-028 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 50 mg INTRAVENOUS ANDA 30 sections
Micafungin HUMAN PRESCRIPTION DRUG LABEL 1 71288-029 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 mg INTRAVENOUS ANDA 30 sections
Micafungin HUMAN PRESCRIPTION DRUG LABEL 1 72572-427 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 mg INTRAVENOUS ANDA 34 sections